Ironwood Pharmaceuticals, Inc. (IRWD)
4.81
-0.04
(-0.82%)
USD |
NASDAQ |
Nov 13, 10:20
Ironwood Pharmaceuticals Enterprise Value : 1.053B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 1.053B |
| November 11, 2026 | 1.056B |
| November 10, 2026 | 1.046B |
| November 09, 2026 | 1.025B |
| November 06, 2026 | 976.60M |
| November 05, 2026 | 917.00M |
| November 04, 2026 | 873.96M |
| November 03, 2026 | 829.26M |
| November 02, 2026 | 822.64M |
| October 30, 2026 | 829.26M |
| October 29, 2026 | 849.13M |
| October 28, 2026 | 847.47M |
| October 27, 2026 | 830.92M |
| October 26, 2026 | 829.26M |
| October 23, 2026 | 822.64M |
| October 22, 2026 | 840.85M |
| October 21, 2026 | 837.54M |
| October 20, 2026 | 850.78M |
| October 19, 2026 | 839.19M |
| October 16, 2026 | 829.26M |
| October 15, 2026 | 873.96M |
| October 14, 2026 | 845.82M |
| October 13, 2026 | 844.16M |
| October 12, 2026 | 872.30M |
| October 09, 2026 | 882.24M |
| Date | Value |
|---|---|
| October 08, 2026 | 890.52M |
| October 07, 2026 | 870.65M |
| October 06, 2026 | 850.78M |
| October 05, 2026 | 854.09M |
| October 02, 2026 | 852.44M |
| October 01, 2026 | 872.30M |
| September 30, 2026 | 907.07M |
| September 29, 2026 | 1.005B |
| September 28, 2026 | 998.53M |
| September 25, 2026 | 1.000B |
| September 24, 2026 | 1.010B |
| September 23, 2026 | 1.023B |
| September 22, 2026 | 1.065B |
| September 21, 2026 | 1.046B |
| September 18, 2026 | 1.038B |
| September 17, 2026 | 1.017B |
| September 16, 2026 | 1.007B |
| September 15, 2026 | 988.61M |
| September 14, 2026 | 1.007B |
| September 11, 2026 | 991.92M |
| September 10, 2026 | 973.74M |
| September 09, 2026 | 990.27M |
| September 08, 2026 | 1.007B |
| September 04, 2026 | 1.022B |
| September 03, 2026 | 1.027B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Xencor, Inc. | 2.606B |
| Viking Therapeutics, Inc. | 2.812B |
| IDEAYA Biosciences, Inc. | 2.235B |
| BioMarin Pharmaceutical, Inc. | 14.45B |
| Inovio Pharmaceuticals, Inc. | 119.79M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 59.84M |
| Revenue (Quarterly) | 133.04M |
| Total Expenses (Quarterly) | 73.20M |
| EPS Diluted (Quarterly) | 0.3558 |
| Gross Profit Margin (Quarterly) | 99.66% |
| Profit Margin (Quarterly) | 44.98% |
| Earnings Yield | 18.57% |
| Operating Earnings Yield | 31.48% |
| Normalized Earnings Yield | 18.54 |